Next Science Limited (ASX: NXS) is a medical technology company headquartered in Sydney, Australia, with commercial operations in Florida, USA. Next Science’s primary focus is the development and continued commercialisation of its proprietary XBIO™ technology to reduce the impact of biofilm-based infections in human health.

Half Year & Full Year Reports

Period Ending Report Webcast Results Release
2023 Annual Report Opens in new window
2023 Full Year Results Opens in new window Opens in new window Opens in new window
2023 Half Year Results Opens in new window Opens in new window
2022 Annual Report Opens in new window
2022 Full Year Results Opens in new window Opens in new window
2022 Half Year Results Opens in new window
2021 Full Year Results Opens in new window Opens in new window
2021 Half Year Results Opens in new window
2021 Annual Report Opens in new window
2020 Annual Report Opens in new window
2020 Full Year Results Opens in new window Opens in new window Opens in new window
2020 Half Year Results Opens in new window Opens in new window Opens in new window

Investor contacts

Investor queries

Next Science Limited
Level 14, Australia Square,
264-278 George Street, Sydney
NSW 2000
Ph: +61 412 292 977
E: [email protected]

Share Registry queries

Automic
Level 5, 126 Phillip Street
Sydney NSW 2000
Email: [email protected]
Ph (within Australia): 1300 288 664
Ph (outside Australia): +61 2 9698 5414

© 2019 Next Science Limited - All Rights Reserved. Solution by MUFG Corporate Markets, a division of MUFG Pension & Market Services

Privacy Policy | Terms of Use | References | Contact Us